Erlotinib in patients with advanced non-small-cell lung cancer: A meta-analysis

Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with single-agent activity in patients with non–small-cell lung cancer (NSCLC). In this article, we updated the evidence of erlotinib in treating advanced NSCLC by adding new results of RCTs publi...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Transl Lung Cancer Res
Hlavní autoři: Gao, Hui, Ding, Xin, Wei, Dong, Cheng, Peng, Su, Xiaomei, Liu, Huanyi, Aziz, Fahad, Wang, Daoyuan, Zhang, Tao
Médium: Artigo
Jazyk:Inglês
Vydáno: Pioneer Bioscience Publishing Company 2012
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4367576/
https://ncbi.nlm.nih.gov/pubmed/25806169
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2012.06.01
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky